Table 1 Baseline demographics and clinical characteristics.
Characteristics | Nivolumab + mFOLFIRINOX (N = 31) |
|---|---|
Sex, male, n (%) | 18 (58.1) |
Age, median (range), years | 59.0 (39–75) |
ECOG performance status, n (%) | |
0 | 21 (67.7) |
1 | 10 (32.3) |
Primary tumour site, n (%) | |
Head | 9 (29.0) |
Body | 14 (45.2) |
Tail | 11 (35.5) |
Number of organs with metastases, n (%) | |
1 | 20 (64.5) |
≥2 | 11 (35.5) |
Site of metastasis, n (%) | |
Liver | 20 (64.5) |
Lung | 5 (16.1) |
Lymph node | 14 (45.2) |
Peritoneum | 6 (19.4) |
Pleura | 1 (3.2) |
CA19-9 (U/mL)a | |
Mean (SD) | 8125.5 (23,883.9) |
Median [Minimum–Maximum] | 1000.0 [1–113,900] |
Any biliary drainage, n (%) | |
No | 24 (77.4) |
Yes | 7 (22.6) |
PD-L1 (CPS), n (%) | |
<1 | 23 (74.2) |
≥1 | 7 (22.6) |
Not quantifiable | 1 (3.2) |
Tumour mutation burden: (Muts/Mbp), n (%) | |
<5 | 20 (64.5) |
≥5 | 4 (12.9) |
Missing | 7 (22.6) |
